Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...140141142143144145146147148149150...858859»
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Journal:  Editorial for "Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells". (Pubmed Central) -  Aug 12, 2023   
    our data indicate that CB-103 is an attractive candidate for clinical investigation in endocrine-resistant, recurrent breast cancers with biomarker-confirmed Notch activity in combination with SERDs and/or CDKis and in TNBCs with biomarker-confirmed Notch activity in combination with taxane-containing chemotherapy regimens. Glioblastoma multiforme (GBM) is the most frequently occurring form of malignant primary brain tumor in adults [...].
  • ||||||||||  Journal:  Combination strategies to overcome drug resistance in FLT acute myeloid leukaemia. (Pubmed Central) -  Aug 12, 2023   
    This study suggests that a multi-targeted intervention involving a CDK4/6 inhibitor with a FLT3 inhibitor or a pan-PI3K inhibitor might be a valuable therapeutic strategy for AML to overcome drug resistance. Moreover, many patients cannot tolerate high doses of the drugs that were studied (quizartinib, palbociclib and PI3K inhibitors) for longer periods, and it is therefore of high significance that the drugs act synergistically and lower doses can be used.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal, Metastases:  Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer. (Pubmed Central) -  Aug 12, 2023   
    Here we show the ability of imaging texture biomarkers before and a few cycles after CDK4/6i therapy, to predict early response and overall survival (OS) on 73 MBC patients with known liver metastases who received palbociclib plus ET from two sites...Compared to RECIST response, delta radiomic features predicted response with area under the curve (AUC)?=?0.72, 95% confidence interval (CI) 0.67-0.88. Our study revealed that radiomics features can predict a lack of response earlier than standard anatomic/RECIST 1.1 assessment and warrants further study and clinical validation.
  • ||||||||||  Review, Journal:  Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events. (Pubmed Central) -  Aug 12, 2023   
    Beyond statins and ezetimibe, different medications targeting LDL-C have been recently approved by regulatory agencies with potential innovative mechanisms of action, including proprotein convertase subtilisin/kexin type 9 modulators (monoclonal antibodies such as evolocumab and alirocumab; small interfering RNA molecules such as inclisiran), ATP-citrate lyase inhibitors (bempedoic acid), angiopoietin-like 3 inhibitors (evinacumab), and microsomal triglyceride transfer protein inhibitors (lomitapide). An understanding of their pharmacological aspects, benefit-risk profile, including impact on hard cardiovascular endpoint beyond LDL-C reduction, and potential advantages from the patient perspective (e.g., adherence) - the focus of this evidence-based review - is crucial for practitioners across medical specialties to minimize therapeutic inertia and support clinical practice.
  • ||||||||||  Journal:  Natural Language Processing for Large-Scale Analysis of Eczema and Psoriasis Social Media Comments. (Pubmed Central) -  Aug 11, 2023   
    Comment volume in r/psoriasis for newer therapeutics (including biologics and apremilast) increased after Food and Drug Administration approval, whereas older therapies such as etanercept, adalimumab, and methotrexate decreased over time...Among psoriasis treatments, calcipotriene and branded calcipotriene/betamethasone foam had the highest sentiment, whereas apremilast had the lowest overall sentiment score. These analyses also identified changes in patient interest levels and sentiment related to eczema and psoriasis treatments, suggesting an area for additional research.
  • ||||||||||  MODULE 3: Future Directions in the Management of MF (LEVEL 3, MEAL THEATER 1; Virtual) -  Aug 11, 2023 - Abstract #SOHO2023SOHO_338;    
    This activity is supported through independent medical education grants from Bristol Myers Squibb, CTI Biopharma Corp, and GlaxoSmithKline. Mechanism of antitumor activity of navitoclax and biological rationale for its evaluation in patients with MF, Published research with navitoclax alone and in combination with ruxolitinib for MF; ongoing Phase III studies, Rationale for the inhibition of BET proteins in patients with MF; mechanisms of action of pelabresib and BMS-986158, Early clinical trial findings and ongoing research with BET inhibitors as monotherapy and in combination with JAK2 inhibitors for MF, Mechanism of action of, available data with and ongoing evaluation of luspatercept as monotherapy or combined with a JAK2 inhibitor for patients with MF and anemia; current role, if any, Published activity and safety data with and ongoing investigation of other novel agents and strategies (eg, bomedemstat, zilurgisertib, selinexor, navtemadlin) in MF,
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Clinical, Journal, Surgery, Metastases:  Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial. (Pubmed Central) -  Aug 10, 2023   
    Mechanism of antitumor activity of navitoclax and biological rationale for its evaluation in patients with MF, Published research with navitoclax alone and in combination with ruxolitinib for MF; ongoing Phase III studies, Rationale for the inhibition of BET proteins in patients with MF; mechanisms of action of pelabresib and BMS-986158, Early clinical trial findings and ongoing research with BET inhibitors as monotherapy and in combination with JAK2 inhibitors for MF, Mechanism of action of, available data with and ongoing evaluation of luspatercept as monotherapy or combined with a JAK2 inhibitor for patients with MF and anemia; current role, if any, Published activity and safety data with and ongoing investigation of other novel agents and strategies (eg, bomedemstat, zilurgisertib, selinexor, navtemadlin) in MF, No abstract available
  • ||||||||||  Discovery of AMG 133, a Novel GIPR Antagonist Antibody & GLP-1 Peptide Conjugate for the Treatment of Obesity () -  Aug 9, 2023 - Abstract #ADCUSA2023ADC_USA_6;    
    To sum up, the prognosis risk model we created not only has good predictive value, but also can provide guidance for accurately predicting the prognosis of ccRCC. Discuss the design of GIPR antibody and GLP-1 peptide bispecific conjugates and site-specific conjugation process to attach GLP-1 analogues to GIPR antibody; View the preclinical data of AMG 133 that demonstrated robust body weight reduction and significantly improved metabolic parameters; Describe AMG 133 Phase I clinical results that showed efficacy and tolerability with desired pharmacokinetic profiles
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Enrollment open, Trial initiation date:  Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer (clinicaltrials.gov) -  Aug 9, 2023   
    P1,  N=30, Recruiting, 
    inhibitors may be beneficial in SJS/TEN, we report a case of etoricoxib-associated SJS with progression to TEN in a 50-year-old woman who was refractory to high-dose sGCS therapy. Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Sep 2023
  • ||||||||||  Lumakras (sotorasib) / Amgen, ladarixin (DF-2156A) / Dompe
    Enrollment open, Phase classification, Metastases:  Ladarixin With Sotorasib in Advanced NSCLC (clinicaltrials.gov) -  Aug 9, 2023   
    P1/2,  N=40, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Sep 2023 Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen, Tremfya (guselkumab) / J&J, Xolair (omalizumab) / Roche, Novartis
    Potential use of anti-IL23 drugs in autoimmune blistering diseases (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1915;    
    However, there are data that support the biological plausibility that they may be effective in this pathology. Therefore, they could be considered in the future as a therapeutic alternative in multirefractory cases, as long as more studies are carried out to evaluate their safety and efficacy for this indication.
  • ||||||||||  The complexity of the treatment journey has no impact on subsequent drug survival of first-time biologics in patients with psoriasis  (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1786;    
    As long as patients experience adequate disease control, these results suggest that conventional systemic treatment still holds value in the management of psoriasis without negatively impacting drug survival of biologics if biologics were to be initiated at a later stage. However, this finding does not account for the impact of the time from disease onset to systemic treatment, whether biological or not, which may hold potential for disease modification.
  • ||||||||||  Efficacy and safety of biological drugs in the treatmens of moderate-to-severe psoriasis in elderly patients (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1657;    
    The results of the present analysis are in line with those of clinical trials randomised clinical trials in the general population and with those of retrospective studies in the elderly population. The data obtained support the hypothesis of the effectiveness of biologic drugs even in patients over 65 and support the appropriateness of their use in clinical practice.
  • ||||||||||  Bimzelx (bimekizumab) / UCB
    Bimekizumab in severe refractory psoriasis in special locations and psoriatic arthritis. (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1608;    
    In addition, two of these patients had presented failure to different classes of biologics. In all of them there was an excellent response with bimekizumab, maintained at 16 weeks, as well as a rapid onset of action that begins in the first 3-4 weeks.
  • ||||||||||  Phase classification, Enrollment change:  SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) -  Aug 8, 2023   
    P1,  N=25, Not yet recruiting, 
    Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026 Phase classification: P2 --> P1 | N=131 --> 25
  • ||||||||||  Ibrance (palbociclib) / Pfizer, capivasertib (AZD5363) / Otsuka, AstraZeneca
    Preclinical, Journal:  Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. (Pubmed Central) -  Aug 6, 2023   
    Despite modified signalling responses, both RB+ and RB- resistant cells responded to combination treatment despite some reduction in relative efficacy and was effective in vivo in palbociclib-resistant PDX models. Collectively these findings demonstrate that simultaneous inhibition of AKT and ER signalling can be effective in models representing palbociclib resistance despite changes in pathway dependency.
  • ||||||||||  Multiple myeloma () -  Aug 5, 2023 - Abstract #JSH2023JSH_8;    
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Enbrel (etanercept) / Pfizer, Amgen, Imbruvica (ibrutinib) / AbbVie, J&J
    Reimbursement, US reimbursement, Journal, Medicare:  Estimated discounts generated by Medicare drug negotiation in 2026. (Pubmed Central) -  Aug 4, 2023   
    The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA Inc. or any of its affiliated or subsidiary entities.